Vertex Pharmaceuticals (VRTX)
(Real Time Quote from BATS)
$396.94 USD
-0.54 (-0.14%)
Updated Apr 29, 2024 01:34 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRTX 396.94 -0.54(-0.14%)
Will VRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Other News for VRTX
Vortex Energy Spearheads Innovative Hydrogen Storage Trial
Global company events calendar
Vortex Energy’s Collaboration with the University of Alberta Receives Alberta Innovates Funding
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older